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Abstract
BACKGROUND: This paper is the short review of our preliminary results obtained with 99mTc-EDDA/HYNIC-TOC. 
MATERIAL AND METHODS: The total of 495 patients with different neuroendocrine tumors were investigated during last few 
years. 
RESULTS: There have been 334 true positive (TP), 73 true negative (TN), 6 false positive (FP) and 82 false negative findings 
(FN). Diagnosis was made according to SPECT findings in 122 patients (25%). The mean T/NT ratio for TP cases was significantly 
higher (p < 0.01) on SPECT (3.12 ± 1.13) than on whole body scan (2.2 ± 0.75). According to our results, overall sensitivity 
of the method is 80%, specificity 92%, positive predictive value 98%, negative predictive value 47% and accuracy 82%. Fifteen 
TP patients underwent therapy with 90Y-DOTATATE.
CONCLUSION: Scintigraphy of neuroendocrine tumors with 99mTc-Tektrotyd is a useful method for diagnosis, staging and 
follow up of the patients suspected to have neuroendocrine tumors. SPECT had important role in diagnosis. It is also helpful 
in the appropriate choice of the therapy, including the peptide receptor radionuclide therapy. In the absence of 68Ga-labeled 
peptides and PET/CT, the special emphasize should be given to application of SPECT/CT as well as to the radioguided surgery.
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Introduction
Neuroendocrine tumors (NETs) are rare tumors originating 
from neural crest, and can be localized in different organs. They 
are slowly growing and therefore not easy to detect. The first 
line diagnosis is made by laboratory analysis and radiological 
(anatomic) imaging modalities such as ultrasonography (US), 
computerized tomography (CT), magnetic resonance imaging 
(MRI) and angiography. The presence of neuroamine uptake 
mechanisms and/or peptide receptors at the cell membrane of 
these tumors allow clinical use of specific radiopharmaceuticals for 
imaging and therapy (theranostics) [1]. Thus, radiolabeled metaio-
dobenzylguanidine (131I-MIBG, 123I-MIBG) have been used to detect 
catecholamine-secreting tumors, while technetium (99mTc)-labeled 
pentavalent dimercaptosuccinic acid (DMSA-V), sestamibi (MIBI) or 
tetrofosmin are used only for diagnosis of medullary thyroid cancer. 
The fact that the majority of NETs express somatostatin recep-
tors provided a possibility for development of various radiolabeled 
somatostatin analogs for their diagnosis and therapy. 
The first in vivo studies were performed with the radioiodinated 
(123I) derivative of octreotide [2] but had drawbacks such as the 
high price, unavailability of 123I, time consuming and deman-
ding preparation and predominantly biliary excretion obscuring 
intra-abdominal tumors. In order to overcome these disadvantages, 
111In-DTPA-D-Phe1-octreotide was developed [3] with a high affinity 
for somatostatin receptors, easy labeling and predominant elimina-
tion by the kidneys. Although 111In pentetreotide was proved to be 
reliable for the detection of NETs, the potential clinical advantage 
of 99mTc labeling in comparison to labeling with 111In, led to develop-
ment of 99mTc-labeled somatostain analogs. 99mTc is not expensive 
and easily available on site. Physical characteristiscs of 99mTc are 
more suitable for imaging with gamma camera, leading to the lower 
radiation burden to the patient allowing the better image quality 
with lower radiation doses. 99mTc-EDDA/HYNIC-TOC (Tektrotyd) 
is a radiopharmaceutical indicated for diagnosis of tumors with 
overexpression of somatostatin receptors (especially subtype 2, 
sstr2). This paper is a short review of our preliminary results obtained 
with this radiopharmaceutical. 
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Material and methods
During last few years, in our Center,somatostatin receptor 
scintigraphy was performed in 495 patients (281 women and 
214 men, mean age 52.3 ± 16.5 years).Indications were: detec-
tion and localization of NETs, staging, determination of the sstr 
status of tumor lesions and follow-up. NET diagnosis were differ-
ent: medullary thyroid carcinomas (48), lung (50), mediastinal (12), 
ovarian (6), kidney (4), hypophysis (10), brain (5), breast (7), para-
ganglioma (12), parathyroid (1), pheochromocytoma (7), NET of 
unknown origin (95), pancreatic (97), gastric (32), colorectal (21), 
small bowel (71), carcinoid of appendix (10), liver (7). 
Scintigraphy of the whole body was performed 2h and 24h after 
i.v. administration of 740 MBq 99mTc-Tektrotyd, Polatom. Investiga-
tion was followed by SPECT of particular region. It was performed 
using 360º orbit, step and shoot mode, at 30 sec per view. The 
acquired data were collected in a 128 x 128 computer matrix and 
reconstructed using filtered back-projections with a Butterworth 
filter (cut-off 0.6 cycles/pixel, order 5) and iterative reconstruction. 
If necessary, the study was supplemented with liver/spleen radiocol-
loid and/or bone diphosphonate scintigraphy. Before study therapy 
with somatostatin analogs was withdrawn, mild laxatives were 
introduced, patients were fasting and were well hydrated. The 
study was performed with ECAM gamma camera and computer 
(ESOFT), using high resolution collimator and one photopeak 
activity (140keV ± 20%). 
Whole body and SPECT images were first evaluated visually by 
two experienced nuclear medicine physicians. Visual appearance 
of an increased focal uptake of tracer in the suspected tumor site 
was considered a positive finding. Subsequent semiquantitative 
analysis was limited to cases with positive findings to compare 
the tumor uptake of radiopharmaceutical to non tumor tissue in 
NETs on SPECT and whole body imaging. For that purpose, tumor 
to non/tumor (T/NT) ratio was calculated after drawing the region 
of interest around the lesion and at the corresponding contralateral 
area on both whole body and SPECT images.
Other imaging techniques were also applied and analysed in 
individual cases (US, MRI, CT, scintigraphy with 99mTc(V)-DMSA, 
131I-MIBG, 99mTc-MDP, 111In-DTPA-octreotide, 99mTc-Sn colloid) as well 
as laboratory analysis.
Results
There have been 334 true positive (TP), 73 true negative (TN), 
6 false positive (FP) and 82 false negative findings (FN) (Table 1). 
Diagnosis was made according to SPECT findings in 122 pa-
tients (25%). The mean T/NT ratio for TP cases was significantly 
higher (p < 0.01) on SPECT (3.12 ± 1.13) than on whole body 
scan (2.2 ± 0.75). According to our results, overall sensitivity of the 
method is 80%, specificity 92%, positive predictive value 98%, nega-
tive predictive value 47% and accuracy 82%. Some of the typical 
results are presented on Figures 1–4. Fifteen TP patients underwent 
therapy with 90Y-DOTATATE (Figure 5).
Discussion
Our results proved high sensitivity, specificity, accuracy, as well 
as positive predictive value. The additional value of SPECT is con-
Table 1. Findings of somatostatin receptor scintigraphy in various NETs
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TP 38 37 11 1 3 6 4 5 7 1 5 80 61 6 12 45 5 7 334
TN 3 6 1 1 1 1 1 1 4 0 1 2 15 8 5 18 5 0 73
FP 0 1 0 0 0 1 0 0 0 0 0 0 0 1 2 1 0 0 6
FN 7 6 0 4 0 2 0 1 1 0 1 13 21 17 2 7 0 0 82
SUM 48 50 12 6 4 10 5 7 12 1 7 95 97 32 21 71 10 7 495
Figure 1. Lung carcinoid. Scintigraphy with 99mTc-Tektrotyd
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firmed in 25% of patients as well as estimation of T/NT ratio. In FP pa-
tients, mainly inflammation was confirmed, as well as physiological 
uptake of radiopharmaceutical increased on particular foci because 
of previous surgery. In patients with FN findings, the cause were par-
ticular hystological tumor characteristics (mainly low differentiated 
tumors, dedifferentiated tumors…) or very small lesions. They were 
mainly confirmed with other nuclear medicine and other (morpho-
logical) methods. Correllation of results of 99mTc-EDDA/HYNIC-TOC 
scintigraphy with results of other imaging methods, as well as with 
laboratory analysis and clinical parameters will be evaluated further.
Our previous results [4] mainly in patients with NET of unknown 
origin or digestive NETs showed sensitivity 87%, specificity 86%, 
positive predictive value 95% negative predictive value 67% and 
accuracy 87%. Our previous results in lung lesions [5, 6] showed 
Figure 2. Bone, liver and lung metastases of NET of unknown origin. 
Scintigraphy with 99mTc-Tektrotyd
Figure 4. Pancreatic NET with liver metastases. Scintigraphy with 
99mTc-Tektrotyd
Figure 5. Multiple metastases in bones, lung, liver. A. scintigraphy 
with 99mTc-Tektrotyd; B. therapy with 90Y-DOTA TATE
Figure 3. Ileal carcinoid with liver metastases. Scintigraphy with 99mTc-
Tektrotyd
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87–88% sensitivity, 84–85% specificity, and 86–88% accuracy. 
This investigation has been reported to be usefull method for the 
detection of NET of different origin and localization, the results were 
similar to those obtained with 111In-pentetreotide as well as reliable 
for the appropriate choice of therapy [7–15].
Results of other authors are similar. Thus, Gabriel et al. [16] in 
GEP tumors obtained sensitivity of 80%, specificity of 94.4% and 
accuracy of 82.9%, and recommended it as an accurate proce-
dure. They [17] revealed a higher sensitivity of this pharmaceutical 
compared with 111In-Octreotide. 
The recent investigations evaluated the potential of using 
this radiopharmaceutical for the imaging of a wide range of pri-
mary and metastatic tumors like hepatocellular carcinomas [20], 
pituitary adenomas, meningiomas [18] liposarcoma, carcinoids, 
breast carcinoma, and lung cancer, as well as the metastases of 
malignant melanomas, pheochromocytoma, prostate cancer, leio-
myosarcoma, pancreatic carcinoma ectopically secreting adreno-
corticotropic hormone, carcinoid of the thymus, mesenchymal 
tumors, parathyroid hyperplasia etc. [19–22]. 
Some other somatostatin analogs, very similar to 99mTc-EDDA/ 
/HYNIC TOC have been recently investigated and recommend-
ed for clinical use [23–30]. Some of them are: 99mTc-EDDA- 
-tricine-HYNIC-NATE, 99mTc-EDDA/HYNIC-octreotate, 99mTc 
(HYNIC-OC, HYNIC-TOC and HYNIC-TATE) and 111In (DTPA-OC 
and DOTA-TATE), 99mTc-demotate, 99mTc-P829. Introduction of 
hybrid systems (SPECT/CT, SPECT/MRI), additionally contrib-
uted to the accuracy and clinical validity of this method [31, 32]. 
A step forward was also made with [33, 34] the potential use of 
radio-guided surgery. 
18F-FDG PET/CT can be used for detecting of low differentiated 
or heterogenous tumors [35]. However, other positron emiting ra-
dionuclides are recommended such as 18F-fluorodopamine, and, 
the most widely used, 68Ga-labeled peptides. In spite of superior 
resolution, short imaging time and imaging whole body in three 
dimensions, the price and availability of use of this pharmaceuti-
cals still do not allow wide application [36, 37].
Conclusion
Our results show that scintigraphy of neuroendocrine tu-
mors with 99mTc-Tektrotyd is a useful method for diagnosis, staging 
and follow up of the patients suspected to have neuroendocrine 
tumors. SPECT had important role in diagnosis. It is also helpful 
in the appropriate choice and monitoring of the therapy, including 
the radionuclide one. In the absence of 68Ga-labeled peptides and 
PET/CT, the special emphasize should be given to application of 
SPECT/CT as well as to the radioguided surgery.Correllation of 
results 99mTc-EDDA/HYNIC-TOC scintigraphy with results of other 
imaging methods, as well as with laboratory analysis and clinical 
parameters will be evaluated further.
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